Efficacy and safety of esaxerenone vs trichlormethiazide for the treatment of uncontrolled essential hypertension in Japanese patients with type 2 diabetes mellitus: a subanalysis of the EXCITE-HT study

Figures

• 

  Fig. 1. Changes from baseline to EOT in morning home BP (full analysis set). A, B overall population, C, D ARB subgroup, E, F CCB subgroup, G, H low UACR (<30 mg/gGr) subgroup, and I, J high UACR (≥30 mg/gCr) subgroup. For panels B, D, F, H, and J, the red dotted line (3.9 mmHg) and blue dotted line (2.1 mmHg) indicate the non-inferiority criteria. Data are LS mean (95% CI). Data for the ARB, CCB, and baseline UACR subgroups are from a post hoc analysis. ARB angiotensin II receptor blocker, BP blood pressure, CCB calcium channel blocker, CI confidence interval, DBP diastolic blood pressure, EOT end of treatment, LS least squares, SBP systolic blood pressure, UACR urinary albumin-to-creatinine ratio

• 

  Fig. 2. Percentage change in geometric mean of UACR from baseline to Week 12 (full analysis set). A overall population, B ARB subgroup, C CCB subgroup, D low UACR (<30 mg/gGr) subgroup, and E high UACR (≥30 mg/gCr) subgroup. Data are shown as geometric mean ± standard deviation (median) for baseline UACR (above the graphs) and percentage change in UACR with 95% CIs (bar graphs). *P < 0.05 versus baseline, paired t-test. **P < 0.01 versus baseline, paired t-test. ***P < 0.001 versus baseline, paired t-test. Data for the ARB, CCB, and baseline UACR subgroups are from a post hoc analysis. ARB angiotensin II receptor blocker, CCB calcium channel blocker, CI confidence interval, UACR urinary albumin-to-creatinine ratio